|
No
|
Age
|
Sex
|
Dasatinib dose
|
BM relapse
|
BCR-ABL mutation
|
EFS, day
|
Outcome / Event (cause of death)
|
|---|
|
1
|
56
|
M
|
100 mg QD
|
No
|
No
|
624*
|
SCT in CMR
|
|
2
|
56
|
M
|
100 mg QD
|
No
|
No
|
149
|
dead (infection)
|
|
3
|
64
|
F
|
100 mg QD
|
No
|
No
|
318
|
CMR
|
|
4
|
68
|
M
|
100 mg QD
|
Yes
|
T315I
|
368
|
dead (PD)
|
|
5
|
67
|
F
|
100 mg QD
|
Yes
|
T315I
|
197
|
dead (PD)
|
|
6
|
22
|
F
|
100 mg QD
|
No
|
No
|
634*
|
SCT in CMR
|
|
7
|
77
|
M
|
50 mg BID
|
Yes
|
T315I
|
221
|
dead (PD)
|
|
8
|
63
|
F
|
50 mg QD
|
Yes
|
T315I
|
106
|
dead (PD)
|
|
9
|
80
|
F
|
100 mg QD
|
No
|
No
|
269
|
CMR
|
|
10
|
32
|
M
|
100 mg QD
|
No
|
No
|
158
|
CMR
|
|
11
|
78
|
M
|
100 mg QD
|
Yes
|
No
|
114
|
dead (PD)
|
- BM, bone marrow; EFS, event-free survival; OS, overall survival; M, male; F, femal; QD, once a day; BID, twice a day; SCT, stem cell transplantation; CMR, complete molecular response; PD, progressive disease; * a date of SCT was evaluated as censoring for analysis of EFS.
